Human study · Research · 4 Jul 2020
WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19
Source: WHO
What the research found
WHO today accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue the trial’s hydroxychloroquine and lopinavir/ritonavir arms. The Solidarity Trial was established by WHO to find an effective COVID-19 treatment for hospitalized patients. The International Steering Committee formulated the recommendation in light of the evidence for hydroxychloroquine vs stan
Evidence level: Human study. A study in people, but an association isn't proof of cause.
More research news
- In mice, fear made hippocampal maps of a safe place and a dangerous place overlap
- In pregnant mice, immune activation at day 12.5 lined up with placental injury and autism-like traits in male fetuses only
- Support cells in brain tissue from 73 people with Parkinson's showed sex differences in energy-gene and myelin-gene activity
- In 10,362 adults, night-to-night swings in sleep timing lined up with a higher risk of serious cardiovascular events
- In a U.S. telephone survey of 442,906 adults, reported cannabis use lined up with higher odds of cardiovascular disease, especially stroke